Evidence map›Paper›PMID 32689948›Full record

ArticleBMC microbiology2020

High prevalence of t895 and t9364 spa types of methicillin-resistant Staphylococcus aureus in a tertiary-care hospital in Mexico: different lineages of clonal complex 5.

C Negrete-González, E Turrubiartes-Martínez, O G Galicia-Cruz, D E Noyola, G Martínez-Aguilar, L F Pérez-González, R González-Amaro, P Niño-Moreno

Open access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Whole-genome sequencing ofMicrobiology spectrum · 2026
    Article
  4. Article
  5. Trends, Seasonality, and the Impact of COVID-19 on ClinicalAntibiotics (Basel, Switzerland) · 2026
    Article
  6. Article
  7. Detection ofPathogens (Basel, Switzerland) · 2024
    Article
  8. Review
  9. Article
  10. Control of Methicillin-ResistantFrontiers in microbiology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

C Negrete-GonzálezSección de Genómica Médica, Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
E Turrubiartes-MartínezSección de Genómica Médica, Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
O G Galicia-CruzDepartamento de Farmacología, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
D E NoyolaDepartamento de Microbiología, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
G Martínez-AguilarUnidad de Investigación Biomédica, Instituto Mexicano del Seguro Social, Durango, Mexico.
L F Pérez-GonzálezHospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico.
R González-AmaroSección de Medicina Molecular y Traslacional, Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
P Niño-MorenoSección de Genómica Médica, Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico. ncarmenp@uaslp.mx.ORCID 0000-0001-7335-7156
Autonomous University of San Luis Potosí · MXHospital Central Dr. Ignacio Morones Prieto · MXMexican Social Security Institute · MX

Funding

CONACyT México 443025CONACyT-Salud México 142334
6 · The paper itself

Abstract

backgroundStaphylococcus aureus is a leading cause of broad-spectrum infections both in the community and within healthcare settings. Methicillin-resistant Staphylococcus aureus (MRSA) has become a global public health issue. The aim of this study was to examine the clinical and molecular characteristics of Staphylococcus aureus isolates and to define the population structure and distribution of major MRSA clones isolated in a tertiary-care hospital in Mexico.

resultsFrom April 2017 to April 2018, 191 Staphylococcus aureus isolates were collected. The frequency of MRSA was 26.7%; these strains exhibited resistance to clindamycin (84.3%), erythromycin (86.2%), levofloxacin (80.3%), and ciprofloxacin (86.3%). The majority of MRSA strains harbored the SCCmec type II (76.4%) and t895 (56.8%) and t9364 (11.7%) were the most common spa types in both hospital-associated MRSA and community-associated MRSA isolates. ST5-MRSA-II-t895 (New York /Japan clone) and ST1011-MRSA-II-t9364 (New York /Japan-Mexican Variant clone) were the most frequently identified clones. Furthermore, different lineages of Clonal Complexes 5 (85.4%) and 8 (8.3%) were predominantly identified in this study.

conclusionOur study provides valuable information about the epidemiology of MRSA in a city of the central region of Mexico, and this is the first report on the association between t895 and t9364 spa types and ST5 and ST1011 lineages, respectively. These findings support the importance of permanent surveillance of MRSA aimed to detect the evolutionary changes of the endemic clones and the emergence of new strains.

Indexed as

AdolescentAdultAnti-Bacterial AgentsChildChild, PreschoolCommunity-Acquired InfectionsCross InfectionDrug Resistance, Multiple, BacterialFemaleHumansInfantInfant, NewbornMaleMethicillin-Resistant Staphylococcus aureusMexicoMicrobial Sensitivity TestsAnti-Bacterial AgentsClonal complex 5-ST1011Methicillin-resistant Staphylococcus aureusNew York/Japan-Mexican variant cloneSCCmec type IISpa type t895Spa type t9364Spa-typing

Identifiers

PMID32689948
PMCPMC7370520
OpenAlexW3042304415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.